Debate-style presentations on challenging issues in dermatology. (Number of sessions: 11)
Note: The position each speaker represents may not necessarily be his/her own professional viewpoint.
Tuesday June 9
09:00 – 10:30
| CN01 | Toxic Epidermal Necrolysis – To Treat or Not To Treat? Immunotherapy Versus Supportive Therapy |
|
Chair: Abdul-Ghani Kibbi (Lebanon) Speaker: Pierre Wolkenstein (France) Position: Immunotherapy Speaker: Jean-ClaudeRoujeau (France) Position: Supportive Therapy |
14:00 – 15:30
| CN02 | Psoriasis: Is Almost Everyone Treatable with Biologics? |
|
Chair: Hamangi Jerajani (India) Speaker: Luigi Naldi (Italy) Position: Not everyone Is treatable with biologics Speaker: Craig Leonardi (United States) Position: Everyone is treatable with biologics |
15:30 – 17:00
| CN03 | Mohs Micrographic Surgery for Nonmelanoma Skin Cancer – Does Every Facial Tumor Really Need It? |
|
Chair: Mary Maloney (United States) Speaker: John Carucci (United States) Position: Every facial tumor needs Mohs surgery Speakers: Michael Bigby (United States) and Brett Coldiron (United States) Position: It is not necessary for every facial tumor to receive Mohs surgery |
Wednesday June 10
09:00 – 10:30
| CN04 | Is There Now Enough Evidence That Controlling Psoriasis Really Decreases Cardiovascular Risk? |
|
Chair: Xuejun Zhang (China) Speaker: Thomas Luger (Germany) Position: Yes there is enough evidence Speakers: Robert Stern (United States) and Tamar Nijsten (Netherlands) Position: No, there is not enough evidence |
| CN05 | Moderate to Severe Bullous Pemphigoid – Total Body Topical Therapy Versus Systemic Agents |
|
Chair: Wolfram Sterry (Germany) Speaker: Pascal Joly (France) Position: Total body topical therapy Speaker: Branka Marinovic (Croatia) Position: Systemic agents |
Thursday June 11
09:00 – 10:30
| CN06 | Is There Any Future for PUVA Therapy? |
|
Chair: Chung-Hong Hu (Chinese Taipei) Speakers: Herbert Hönigsmann (Austria) and Berhard Ortel (United States) Position: Yes, there is a future Speaker: James Ferguson (United Kingdom) Position: No, there is no future |
| CN07 | Laboratory Testing for Chronic Urticaria – Minimal Versus Extensive |
|
Chair: Hee Chul Eun (Korea) Speaker: Nicholas Soter (United States) Position: Minimal testing Speakers: Torsten Zuberbier (Germany) and Kiran Godse (India) Position: Extensive testing |
Friday June 12
09:00 – 10:30
| CN08 | Patient Care is Enhanced When Dermatologists Routinely Follow Guidelines of Care. Pro or Con? |
|
Chair: Marcia Ramos e Silva (Brazil) Speaker: Alexander Nast (Germany) Position: Guidelines should be routinely followed Speakers: Stephen Stone (United States) and Lucinda Buescher (United States) Position: Routinely following guidelines does not enhance patient care |
| CN09 | Actinic Keratoses – Is Routine Eradication Necessary? |
|
Chair: Jorge Ocampo (Mexico) Speaker: Neal Bhatia (United States) Position: Routine eradication is necessary Speaker: Clay Cockerell (United States) Position: Routine eradication is unnecessary |
Saturday June 13
09:00 – 10:30
| CN10 | The Cutaneous Melanoma Epidemic – Is it Real or an Artifact of Aggressive Diagnosis? |
|
Chair: Francisco Camacho (Spain) Speaker: Earl Glusac (United States) Position: The melanoma epidemic is mostly due to aggressive Speakers: Jason Rivers (Canada) and Darrell Rigel (United States) Position: The melanoma epidemic is real |
14:00 – 15:30
| CN11 | Global Dermatology in 2025 – Innovative Expensive Treatments for a Few Versus Low-cost Medications for Everyone? |
|
Chair: Christopher Griffiths (United Kingdom) Speakers: Warren Piette (United States) and Joerg Albrecht (United States) Position: Low cost medications for everyone have the greatest impact on our patients Speaker: Bruce Strober (United States) Position: Innovative treatments enhance dermatology and are temporarily expensive |